title: [Evaluation of late cardiac toxicity of anthracycline in childhood].
abstract: OBJECTIVE
  To examine left ventricular function in patients previously treated with anthracycline for childhood malignancies. To evaluate the importance of age at the beginning of therapy, of total cumulative dose and of length of follow-up on late cardiac effects of anthracyclines.
  
  
  METHODS
  Cross sectional echocardiography study of left ventricular function.
  
  
  METHODS
  Eighteen patients surviving between 1 and 9 years (median 2 years) from end of chemotherapy. Cumulative doses were between 120 and 550 mg/mq (median 275 mg/mq). Age at the beginning of chemotherapy was between 1.8 and 12.25 years (median 5.17 years). Nineteen healthy subjects were also studied as control group.
  
  
  METHODS
  Assessment of transmitral diastolic pulsed wave Doppler flow patterns and of transaortic pulsed wave Doppler flow patterns. Evaluation of systolic function measured by M-mode echocardiography.
  
  
  RESULTS
  Patients compared to controls showed a significative reduction of Ejection Fraction, of Shortening Fraction, of peak early phase to peak atrial phase filling velocity ratio and an increase of peak atrial phase filling velocity and of time-velocity integral of peak filling atrial phase. These alterations were more evident at doses higher than 250 mg/m2, in patients whose therapy started before 5 years of age and in patients whose follow-up was longer than 5 years.
  
  
  CONCLUSIONS
  Significant abnormalities of systolic and diastolic function may appear some years after the end of anthracycline therapy for childhood malignancies. Therefore patient's continued follow-up is necessary in order to guide patient care and to better chemotherapeutic protocols.
authors.affiliation: Sezione Autonoma di Cardiologia Pediatrica, Università Cattolica del Sacro Cuore, Roma.
authors.forename: G
authors.initials: G
authors.lastname: Butera
authors.forename: D
authors.initials: D
authors.lastname: Piciacchia
authors.forename: M
authors.initials: M
authors.lastname: Chessa
authors.forename: C
authors.initials: C
authors.lastname: Condoluci
authors.forename: A
authors.initials: A
authors.lastname: Tornesello
authors.forename: A B
authors.initials: AB
authors.lastname: Delogu
authors.forename: S
authors.initials: S
authors.lastname: Mastrangelo
authors.forename: A
authors.initials: A
authors.lastname: Cipriani
mesh_terms: D000367:Age Factors; D018943:Anthracyclines / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003627:Data Interpretation, Statistical; D003971:Diastole / Q000187:drug effects; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D013599:Systole / Q000187:drug effects; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D018943:Anthracyclines